Potential new drug to mitigate SARS-CoV-2 infection consequences

covid drug
Credit: Pixabay/CC0 Public Domain

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Center for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

In the coming year, a team led by the researchers of the UMA Iván Durán and Fabiana Csukasi will study how 4-Phenylbutiric acid (4-PBA) treatment modulates the produced in severe cases of COVID-19. The project has been financed by the COVID-19 Fund of the Government of Andalusia, with an initial endowment of EUR90,000 and the possibility of a three-year renewal. First results have already been published in the scientific journal Cytokine and Growth Factors Review.

The inflammatory process identified in severe cases of coronavirus causes an uncontrolled and excessive release of cytokines—molecules in charge of organizing the body's defenses—which could even trigger vascular hyperpermeability and multiorgan failure. Controlling such cytokine "storm," through those controlling them, that is, the , is precisely what these researchers of the UMA propose.

"When cells are stressed by infection, they call the cytokines, and the more stressed they are, the more persistent they become, provoking this uncontrolled inflammation. Hence, one possible treatment for COVID-19 is to reduce ," explains Durán.

According to the researcher, repurposing the 4-PBA anti-stress drug, approved for clinical use against other diseases and, hence, easy to apply clinically, could modulate such cellular stress, which is also present in pathologies like diabetes, aging or carcinogenesis, which, in turn, are classified as for COVID-19.

Identifying risk groups

"Our preliminary results conducted on animal models have demonstrated that 4-PBA fully curbs mortality caused by respiratory failure derived from cellular stress," says the professor of the UMA, who further explains that these first studies have also identified the resident protein "BiP" (Binding Immunoglobulin Protein)—a stress blood marker—as indicator of cellular stress situations, likely to be explored and measured in affected patients.

This way, as Durán points out, BiP levels, apart from determining the efficacy of 4-PBA treatment, could serve as early indicators of COVID-19 risk groups, establishing a correlation between high levels and the inflammatory severity after the viral infection.

"There are people already suffering from diseases that cause cellular stress, and when they become infected with coronavirus, they are more likely to fall ill or die. Therefore, if we know that the patient suffers from cellular , we can kill two birds with one stone: we can detect susceptibility before infection occurs and know how to treat it in due time," says Durán.

More information: Fabiana Csukasi et al. Should we unstress SARS-CoV-2 infected cells?, Cytokine & Growth Factor Reviews (2020). DOI: 10.1016/j.cytogfr.2020.06.011

Provided by University of Malaga
Citation: Potential new drug to mitigate SARS-CoV-2 infection consequences (2020, September 18) retrieved 16 June 2024 from https://medicalxpress.com/news/2020-09-potential-drug-mitigate-sars-cov-infection.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Does the COVID-19 cytokine storm exist?


Feedback to editors